Oramed Pharmaceuticals started at buy with $27 stock price target at Canaccord Genuity

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply